Nature Reviews Drug Discovery Publishes mRNA Therapeutics 2.0 Review After 10 Years of Trials
Updated
Updated · Nature.com · Jun 3
Nature Reviews Drug Discovery Publishes mRNA Therapeutics 2.0 Review After 10 Years of Trials
2 articles · Updated · Nature.com · Jun 3
Summary
Nature Reviews Drug Discovery published a review arguing mRNA drugs are moving beyond vaccines into enzyme replacement, cancer immunotherapy, genome editing and immune-cell reprogramming.
A decade of clinical studies has clarified the main bottlenecks: in vivo delivery, inflammatory reactions that limit repeat dosing, and poor targeting to organs beyond the liver.
The review highlights advances it says could unlock “mRNA therapeutics 2.0,” including clinically tractable delivery systems, immune-silent mRNA-vehicle formulations and organ-selective delivery technologies.
It frames the next phase of the field as increasingly interdisciplinary, with mRNA platforms converging with gene and cell therapies to treat both rare and common diseases.
mRNA therapies promise cures for diseases like cancer, but will these revolutionary treatments be accessible and affordable for everyone?
mRNA's next frontier is delivering drugs beyond the liver. Which company will be first to master this targeted delivery challenge?
As mRNA cancer vaccines emerge, can scientific fact overcome the viral 'turbo cancer' misinformation threatening their future?
mRNA Therapeutics 2.0: From Pandemic Breakthroughs to Precision Medicine and Global Access
Overview
The report highlights the unveiling of 'mRNA Therapeutics 2.0' following the publication of a landmark review in 2026, marking a new era for mRNA-based medicine. This breakthrough is the result of decades of scientific research and was accelerated by the global health crisis of COVID-19. Early challenges in mRNA delivery and stability were overcome through key technological advancements, enabling rapid vaccine development and expanding mRNA’s potential beyond infectious diseases to cancer and rare genetic disorders. The report also discusses ongoing innovations in targeted delivery, regulatory challenges, and the promise of precision medicine powered by artificial intelligence.